1. Home
  2. NSPR vs NRXS Comparison

NSPR vs NRXS Comparison

Compare NSPR & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo InspireMD Inc.

NSPR

InspireMD Inc.

HOLD

Current Price

$0.72

Market Cap

72.1M

Sector

Health Care

ML Signal

HOLD

Logo Neuraxis Inc.

NRXS

Neuraxis Inc.

SELL

Current Price

$7.08

Market Cap

78.9M

Sector

N/A

ML Signal

SELL

Company Overview

Basic Information
Metric
NSPR
NRXS
Founded
2005
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
72.1M
78.9M
IPO Year
2009
2023

Fundamental Metrics

Financial Performance
Metric
NSPR
NRXS
Price
$0.72
$7.08
Analyst Decision
Buy
Strong Buy
Analyst Count
1
1
Target Price
$4.00
$13.00
AVG Volume (30 Days)
157.0K
115.9K
Earning Date
05-04-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
22.13
EPS
N/A
N/A
Revenue
$2,310,000.00
$3,569,282.00
Revenue This Year
$57.98
$172.91
Revenue Next Year
$95.41
$115.71
P/E Ratio
N/A
N/A
Revenue Growth
N/A
32.89
52 Week Low
$0.69
$2.20
52 Week High
$2.93
$9.33

Technical Indicators

Market Signals
Indicator
NSPR
NRXS
Relative Strength Index (RSI) 28.77 50.58
Support Level N/A $6.92
Resistance Level $1.04 $7.79
Average True Range (ATR) 0.09 0.38
MACD -0.00 0.01
Stochastic Oscillator 5.72 71.96

Price Performance

Historical Comparison
NSPR
NRXS

About NSPR InspireMD Inc.

InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.

About NRXS Neuraxis Inc.

Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).

Share on Social Networks: